期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

帕洛诺司琼与昂丹司琼用于预防妇科肿瘤术后恶心呕吐的疗效比较 被引量：2

下载PDF
导出
摘要 目的比较帕洛诺司琼与昂丹司琼预防妇科肿瘤术后恶心、呕吐的临床疗效。方法选择60例ASAⅠ～Ⅱ级择期妇科肿瘤手术病人,随机分为两组,每组30例,在手术开始关腹时,分别缓慢静脉注射昂丹司琼8mg(A组)、帕洛诺司琼0.25mg(B组),两组患者术后均使用静脉镇痛泵,内含芬太尼0.016mg/kg,无任何止吐药。结果在术后24h内恶心呕吐比较差异有统计学意义(P<0.05),B组优于A组。结论帕洛诺司琼对恶心呕吐的预防作用优于昂丹司琼。
作者 许仄平 顾连兵
机构地区 江苏省肿瘤医院
出处 《齐齐哈尔医学院学报》 2011年第7期1064-1065,共2页 Journal of Qiqihar Medical University
关键词 帕洛诺司琼 昂丹司琼 恶心 呕吐 妇科肿瘤手术
分类号 R442.1 [医药卫生—诊断学]
  • 相关文献

参考文献8

  • 1罗霞,彭六保,谭重庆,万小敏,崔巍,曹俊华.帕洛诺司琼:第2代5-羟色胺3受体拮抗药[J].中国新药与临床杂志,2009,28(9):649-653. 被引量：11
  • 2Aapro MS,Grunberg SM,Manikhas GM,et al.A phase Ⅲ,double-blind,randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy[J].Ann Oncol,2006,17(9):1441-1449.
  • 3陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量：48
  • 4Aapro MS.Palonosetron as an anti-emetic and anti-nausea agent in oncology[J].Ther Clin Risk Manag,2007,3(6):1009-1020.
  • 5De Leon A.Palonosetron(Aloxi):a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomi-ting[J].Proc(Bayl Univ Med Cent),2006,19(4):413-416.
  • 6Kloth DD.New pharmacologic findings for the treatment of PONV and PDNV[J].Am J Health Syst Pharm,2009,66(1):11-18.
  • 7Rojas C,Stathis M,Thomas AG,et al.Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor[J].Anesth Analg,2008,107(2):469-478.
  • 8Navari RM.Palonosetron:a second-generation 5-hydroxytry-ptamine receptor antagonist[J].Future Oncol,2006,2(5):591-602.

二级参考文献44

  • 1陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量：48
  • 2SHARMA R, TOBIN P, CLARKE SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea [J]. Lancet Oncol, 2005, 6(2) : 93-102.
  • 3HESKETH PJ. New treatment options for chemotherapy-induced nausea and vomiting[J]. Support Care Cancer, 2004, 12(8): 550-554.
  • 4HERRSTEDT J, KOELLER JM, ROILA F, et al. Acute emesis: moderately emetogenic chemotherapy [J]. Support Care Cancer, 2005, 13(2): 97-103.
  • 5KRIS MG, HESKETH PJ, HERRSTEDT J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy[J]. Support Care Cancer, 2005, 13(2): 85-96.
  • 6American Society of Clinical Oncology, KRIS MG, HESKETH PJ, et al.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006[J]. J Clin Oncol, 2006, 24(18) : 2932-2947.
  • 7ROILA F, WARR D, CLARK-SNOW RA, et ol. Delayed emesis: moderately emetogenic chemotherapy [J]. Support Care Cancer, 2005, 13(2) : 104-108.
  • 8AAPRO MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology[J]. Ther Clin Risk Manag, 2007, 3(6): 1009- 1020.
  • 9de LEON A. Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting[J]. Proc (Bayl Univ Med Cent), 2006, 19(4): 413-416.
  • 10KLOTH DD. New pharmacologic findings for the treatment of PONV and PDNV [J]. Am J Health Syst Pharm, 2009, 66(1 Suppl 1): S11-S18.

共引文献56

同被引文献28

  • 1Katsuhito Hori,Norihiro Kobayashi,Hitoshi Atsumi,Akira Nagayama,Masako Kondoh,Ichiro Noge,Midori Kimura,Hiroaki Utsugi,Tsuyoshi Iwasaki,Masaki Nakamura,Tomomi Kimura.Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network[J].Supportive Care in Cancer.2014(4)
  • 2Tiene G. M. Bauters,Joris Verlooy,Hugo Robays,Yves Benoit,Geneviève Laureys.Emesis control by aprepitant in children and adolescents with chemotherapy[J].International Journal of Clinical Pharmacy.2013(6)
  • 3Alessandra Fabi,Paola Malaguti.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting[J].Expert Opinion on Pharmacotherapy.2013(5)
  • 4Camilo Rojas,Barbara S. Slusher.Pharmacological mechanisms of 5-HT 3 and tachykinin NK 1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting[J].European Journal of Pharmacology (-).2012(1-3)
  • 5Winnie Yeo,Chan.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients[J].Breast Cancer: Targets and Therapy (default).2011(default)
  • 6APFEL C C, LAARA E, KOIVURANTA M, et at. A simplied risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers [J]. Anesthesiology, 1999, 91(3): 693-700.
  • 7KOIVUSALOAM, KELLOKUMPU I, LINDGREN L. Gasless laparoscopic cholecystectomy: comparison of postoperative recovery with conventional technique [J]. Br J Anaesth, 1996, 77(5): 576-580.
  • 8JOSEPHS L G, ESTE-MCDONALD J R. BIRETT D H, et al. Diagnostic laparoscopy increases Intracranial pressure [J]. J Trauma, 1994, 36(6): 815-819.
  • 9HSU E S. A review of granisetron, 5-hydroxytryptamine 3 receptor antagonists, and other antiemetics [J]. Am J Ther, 2010, 17(5): 476-486.
  • 10MASSA E, ASTARA G, MADEDDU C, et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pretreated patients who have failed to respond to a previous antiemetic treatment:comparison between elderly and non-elderly patient response [J]. Crit Rev Oncol Hematol, 2009, 70(1): 83-91.

引证文献2

二级引证文献27

齐齐哈尔医学院学报
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部